After careful consideration of the available data and feedback received during the FDA Advisory Committee meeting, the FDA required a boxed warning and a revision
Montelukast (Singulair and generics) already includes warnings about mental health side effects but the FDA decided to implement a boxed warning following
After careful consideration of the available data and feedback received during the FDA Advisory Committee meeting, the FDA required a boxed warning and a revision
Food and Drug Administration (FDA) announced it is requiring a boxed warning for montelukast due to mental health
The FDA ordered a “Boxed Warning,” which is the most prominent warning label, be added to prescribing information
47102/annals-acadmedsg
Singulair has been on the market for 25 years, throughout which multiple studies have shown a correlation between Singulair usage and the development of
Montelukast está aprobado por la FDA para tratar el asma y las alergias
Boxed warnings (formerly known as Black Box Warnings) are the highest safety-related warning that medications can have assigned by the Food and Drug Administration
1)
1)
Following the FDA’s decision to require a Box Warning on Singulair in The boxed warning, the FDA’s most prominent warning, advises physicians avoid prescribing the therapy for patients with mild symptoms—particularly patients with allergic rhinitis
Montelukast is currently approved by the FDA to prevent asthma exacerbation and symptoms including wheezing and
S